Clinical Trials | September 23, 2025
Akums demonstrates clinical versatility of Lacosamide in epilepsy care
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
The new lineup includes CereTom Elite, OmniTom Elite, OmniTom Elite PCD, and BodyTom 32/64
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
Apollo has also announced plans to add over 4,300 beds in the next five years with an investment of over Rs. 7,600 crore
Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Subscribe To Our Newsletter & Stay Updated
